TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07290088: An Open Label, Multicenter, Safety and Efficacy Phase II/III Study of PRL3-Zumab in Solid Tumor Patients

Sponsor: Intra-IMMUSG Pte Ltd · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 52 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$17,303,748

Rescue Site Savings

+$11,441,892

Unlock Full NCT07290088 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07290088 Rescue Dossier →